CDA | Evidence Driven
CDA | Evidence Driven

abiraterone acetate and prednisolone

Details

Files
Generic Name:
abiraterone acetate and prednisolone
Project Status:
Complete
Therapeutic Area:
High-risk non-metastatic prostate cancer
Manufacturer:
n/a
Call for patient/clinician input open:
Brand Name:
n/a
Project Line:
Reimbursement Review
Project Number:
PX0291-000 - PC0291-000
Call for patient/clinician input closed:
NOC Status at Filing:
Post NOC
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
n/a
Submission Type:
Non-sponsored Submission
Fee Schedule:
N/A
Indications:
For the treatment of high-risk non-metastatic prostate cancer.
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
Key Milestones2
Call for patient/clinician input open06-Jun-22
Call for patient/clinician input closed29-Jul-22
Clarification:

- Patient input submission received from the Canadian Cancer Society

Call for industry input open06-Jun-22
Call for industry input closed29-Jul-22
Review initiated06-Jun-22
Expert committee meeting (initial)29-Jun-23
Draft recommendation posted for stakeholder feedback20-Jul-23
End of feedback period03-Aug-23
Final recommendation posted08-Sep-23
CADTH review report(s) posted08-Sep-23

Files

Recommendation and Reasons View PDF
Stakeholder Input View PDF
Stakeholder Feedback on Draft Recommendation View PDF
Responses to Questions From the Drug Programs View PDF
Clinical and Pharmacoeconomic Combined Report View PDF
Last Updated : September 11, 2023